Postmenopausal atrophic vaginitis 1 N95.2 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. 2 The 2019 edition of ICD-10-CM N95.2 became effective on October 1, 2018. 3 This is the American ICD-10-CM version of N95.2 - other international versions of ICD-10 N95.2 may differ.
Estrogen excess. E28.0 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2019 edition of ICD-10-CM E28.0 became effective on October 1, 2018. This is the American ICD-10-CM version of E28.0 - other international versions of ICD-10 E28.0 may differ.
E28.0 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2021 edition of ICD-10-CM E28.0 became effective on October 1, 2020. This is the American ICD-10-CM version of E28.0 - other international versions of ICD-10 E28.0 may differ.
Hormone replacement therapy. Z79.890 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2020 edition of ICD-10-CM Z79.890 became effective on October 1, 2019. This is the American ICD-10-CM version of Z79.890 - other international versions of ICD-10 Z79.890 may differ.
ICD-10 code Z79. 890 for Hormone replacement therapy is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
ICD-10-CM Diagnosis Code N76 N76.
N95. 2 - Postmenopausal atrophic vaginitis | ICD-10-CM.
ICD-10 Code for Other long term (current) drug therapy- Z79. 899- Codify by AAPC. Factors influencing health status and contact with health services. Persons with potential health hazards related to family and personal history and certain conditions influencing health status.
N90. 89 - Other specified noninflammatory disorders of vulva and perineum | ICD-10-CM.
Vaginal atrophy (atrophic vaginitis) is thinning, drying and inflammation of the vaginal walls that may occur when your body has less estrogen. Vaginal atrophy occurs most often after menopause. For many women, vaginal atrophy not only makes intercourse painful but also leads to distressing urinary symptoms.
Each gram of ESTRACE (estradiol vaginal cream, USP, 0.01%) contains 0.1 mg estradiol in a nonliquefying base containing purified water, propylene glycol, stearyl alcohol, white ceresin wax, mono- and di-glycerides, hypromellose 2208 (4000 cps), sodium lauryl sulfate, methylparaben, edetate di-sodium and tertiary- ...
Premarin (conjugated estrogens) replaces estrogen hormones that your body loses during menopause. Replacing estrogen strengthens bones, relieves symptoms of menopause, and helps with the pain that happens with some forms of advanced breast and prostate cancer.
The ICD-10 section that covers long-term drug therapy is Z79, with many subsections and specific diagnosis codes. Because Plaquenil does not have its own specific category, clinicians should use Z79. 899—Other Long Term (Current) Drug Therapy.
ICD-10-PCS GZ3ZZZZ is a specific/billable code that can be used to indicate a procedure.
For the monitoring of patients on methadone maintenance and chronic pain patients with opioid dependence use diagnosis code Z79. 891, suspected of abusing other illicit drugs, use diagnosis code Z79. 899.
The NDC Code 0046-0872-21 is assigned to “Premarin Vaginal” (also known as: “Conjugated Estrogens”), a human prescription drug labeled by “Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.”. The product's dosage form is cream, and is administered via vaginal form.
The labeler code, product code, and package code segments of the National Drug Code number, separated by hyphens. Asterisks are no longer used or included within the product and package code segments to indicate certain configurations of the NDC.
PREMARIN Vaginal Cream (0.5 g) is administered intravaginally in a twice-weekly (for example, Monday and Thursday) continuous regimen or in a cyclic regimen of 21 days of therapy followed by 7 days off of therapy [see Dosage Forms and Strengths (3)].
PREMARIN Vaginal Cream is administered intravaginally in a cyclic regimen (daily for 21 days and then off for 7 days). Generally, women should be started at the 0.5 g dosage strength. Dosage adjustments (0.5 to 2 g) may be made based on individual response [see Dosage Forms and Strengths (3)].
The primary analysis, using case-control comparisons, included 12,110 cancer cases from the 17 prospective studies.
Vaginal yeast infection. Reactions from inserting PREMARIN Vaginal Cream, such as vaginal burning, irritation, and itching. These are not all the possible side effects of PREMARIN Vaginal Cream. For more information, ask your healthcare provider or pharmacist for advice about side effects.
Overdosage of estrogen may cause nausea, vomiting, breast tenderness, abdominal pain, drowsiness and fatigue, and withdrawal bleeding may occur in women. Treatment of overdose consists of discontinuation of PREMARIN therapy with institution of appropriate symptomatic care.
PREMARIN Vaginal Cream should not be used during pregnancy [see Contraindications (4)]. There appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins as an oral contraceptive inadvertently during early pregnancy.
PREMARIN Vaginal Cream exposure has been reported to weaken latex condoms. The potential for PREMARIN Vaginal Cream to weaken and contribute to the failure of condoms, diaphragms, or cervical caps made of latex or rubber should be considered.